Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 501-510

  Li, Jingjie ^a   Liang, Xiaoyan ^a   Yang, Xing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Gemcitabine resistant pancreatic cancer; JNK; PI3K Akt NF B; Ursolic acid

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYTOCHROME C; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; URSOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, NUDE; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863432050     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1827     Document Type: Article

References (52)

1. Stathis A and Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172, 2010.
2. Campbell PJ, Yachida S and Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113, 2010.
3. Herrmann R and Jelic S: Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 (Suppl 2): I25-I26, 2008.
4. Rosewicz S and Wiedenmann B: Pancreatic carcinoma. Lancet 349: 485-489, 1997. (Pubitemid 27077838)
5. Burris HR, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
6. Ou YQ, Zhu W, Li Y, et al: Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity. Acta Pharmacol Sin 31: 73-80, 2010.
7. Ina S, Hirono S, Noda T and Yamaue H: Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kDa is associated with intrinsic chemoresistance. Pancreas 39: 473-485, 2010.
8. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
9. Liu J: Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 100: 92-94, 2005.
10. Liu J: Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49: 57-68, 1995.
11. Shih YH, Chein YC, Wang JY and Fu YS: Ursolic acid protects hippocampal neurons against kainate-induced excitotoxicity in rats. Neurosci Lett 362: 136-140, 2004.
12. Chung YK, Heo HJ, Kim EK, et al: Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol Cells 11: 137-143, 2001.
13. Tsai SJ and Yin MC: Antioxidative and anti-inflammatory protection of oleanolic acid and ursolic acid in PC12 cells. J Food Sci 73: H174-H178, 2008.
14. Somova LO, Nadar A, Rammanan P and Shode FO: Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 10: 115-121, 2003. (Pubitemid 36433204)
15. Cha HJ, Bae SK, Lee HY, et al: Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 56: 2281-2284, 1996.
16. Zhang Y, Kong C, Zeng Y, et al: Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol Carcinog 49: 374-385, 2010.
17. Yang L, Liu X, Lu Z, et al: Ursolic acid induces doxorubicin-resistant HepG2 cell death via the release of apoptosis-inducing factor. Cancer Lett 298: 128-138, 2010.
18. Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281: 162-170, 2009.
19. Manu KA and Kuttan G: Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expressions and suppressing NF-kappaB mediated activation of bcl-2 in B16F-10 melanoma cells. Int Immunopharmacol 8: 974-981, 2008.
20. Wang JS, Ren TN and Xi T: Ursolic acid induces apoptosis by suppressing the expression of FoxM1 in MCF-7 human breast cancer cells. Med Oncol 29: 10-15, 2012.
21. Zhu W, Ou Y, Li Y, et al: A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol 75: 812-819, 2009.
22. Li J, Zhu W, Leng T, et al: Triptolide-induced cell cycle arrest and apoptosis in human renal cell carcinoma cells. Oncol Rep 25: 979-987, 2011.
23. He D, Xu Q, Yan M, et al: The NF-kappaB inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 9: 343, 2009.
24. Stairs DB, Nakagawa H, Klein-Szanto A, et al: Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS One 3: e3534, 2008.
25. Xia Y, Liu Y, Wan J, et al: Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem 52: 6083-6096, 2009.
26. Jonckheere N, Fauquette V, Stechly L, et al: Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. Br J Cancer 101: 637-644, 2009.
27. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H and Tashiro S: Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38-44, 2004. (Pubitemid 38032243)
28. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001. (Pubitemid 32225829)
29. Zhang YX, Kong CZ, Wang LH, et al: Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells involving activation of JNK-induced Bcl-2 phosphorylation and degradation. J Cell Biochem 109: 764-773, 2010.
30. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
31. Falasca M: PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des 16: 1410-1416, 2010.
32. Arlt A, Gehrz A, Muerkoster S, et al: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003. (Pubitemid 36712936)
33. Wang X, Yang Y, Xu C, et al: CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel. Int J Gynecol Cancer 21: 996-1003, 2011.
34. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK and Brard L: Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One 3: e2303, 2008.
35. Welch SA and Moore MJ: Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? J Clin Oncol 25: 2159-2161, 2007. (Pubitemid 46954636)
36. Mamaghani S, Patel S and Hedley DW: Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 9: 132, 2009.
37. Shan JZ, Xuan YY, Ruan SQ and Sun M: Proliferation-inhibiting and apoptosis-inducing effects of ursolic acid and oleanolic acid on multi-drug resistance cancer cells in vitro. Chin J Integr Med 17: 607-611, 2011.
38. Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Cell Biol 19: 142-149, 2007. (Pubitemid 46386399)
39. Perugini RA, McDade TP, Vittimberga FJ and Callery MP: Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 90: 39-44, 2000. (Pubitemid 30317175)
40. Zhang YX, Kong CZ, Wang HQ, Wang LH, Xu CL and Sun YH: Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. Biochimie 91: 1173-1179, 2009.
41. Kroemer G and Reed JC: Mitochondrial control of cell death. Nat Med 6: 513-519, 2000. (Pubitemid 30305900)
42. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998. (Pubitemid 28406815)
43. Teraishi F, Zhang L, Guo W, et al: Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett 579: 6681-6687, 2005. (Pubitemid 41682458)
44. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
45. Garcia-Echeverria C and Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526, 2008.
46. Kane LP, Shapiro VS, Stokoe D and Weiss A: Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9: 601-604, 1999.
47. Mayo LD and Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603, 2001. (Pubitemid 32928774)
48. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982, 2001. (Pubitemid 34428742)
49. Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511, 1998. (Pubitemid 28553242)
50. Pham NA, Tsao MS, Cao P and Hedley DW: Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas 35: E16-E26, 2007. (Pubitemid 47482532)
51. Ng SS, Tsao MS, Nicklee T and Hedley DW: Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7: 3269-3275, 2001. (Pubitemid 32963853)
52. Sultana N: Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product. J Enzyme Inhib Med Chem 26: 616-642, 2011.